The Persistent Challenge of Cardiogenic Shock Complicating Acute Myocardial Infarction: Insights From a Korean Nationwide Registry Authors: Minju Han, Jeehoon Kang Published: 2026 Cardiogenic shock (CS) remains the leading cause of death in patients with acute myocardial infarction (AMI), with reported in-hospital mortality rates of 40–50%. Despite substantial advances in reperfusion therapy, pharmacologic treatment, and critical care, outcomes for CS have improved only modestly.1) In this issue of the Korean Circulation Journal, Song et al.1) report a 10-year analysis of CS complicating AMI using 2 large Korean nationwide registries, the KAMIR-NIH (2011–2015) and the KAMIR-V (2016–2020), encompassing nearly 29,000 patients with AMI.1) The overall prevalence of CS after AMI declined from 12.5% in the early period to 9.6% in the late period. Over the same period, percutaneous coronary intervention (PCI) increased markedly, potent P2Y12 inhibitor use expanded, and intra-aortic balloon pump (IABP) utilization decreased (22.4% to 6.7%). The critical finding of this study is the divergence in outcomes by shock phenotype. In-hospital mortality improved for CS present at hospital admission (before-admission cardiogenic shock [ba-CS]) from 25.1% to 17.0%, but did not change for CS that developed during hospitalization (during admission cardiogenic shock [da-CS], 30.3% to 32.9%). This trend was maintained at 1 year, with mortality decreased in ba-CS (33.4% to 21.9%) but unchanged in da-CS (37.3% to 40.1%). da-CS was also independently associated with the highest risk of in-hospital mortality (adjusted odds ratio [OR], 15.8), higher than ba-CS (adjusted OR, 9.4). Why does da-CS persistently carry poor prognosis, despite the advances that have benefited ba-CS? The authors suggest that da-CS may involve a more rapid and severe systemic inflammatory response compared to ba-CS with compounding hemodynamic deterioration. Furthermore, the possibility of iatrogenic contributions including reperfusion injury and the adverse hemodynamic effects of medications cannot be excluded. Meanwhile, the predictors of da-CS development (older age, ST-elevated myocardial infarction, multivessel disease, low Thrombolysis in Myocardial Infarction flow at the initial index angiogram prior to PCI) and the protective effect of successful PCI underscore that early risk stratification and effective revascularization are the cornerstones of prevention of in-hospital shock development. The mechanical circulatory support (MCS) landscape described in this study merits particular attention. There was a huge decline in IABP use (from 22.4% to 6.7%) and a concurrent rise in extracorporeal membrane oxygenation (ECMO) utilization (from 9.3% to 12.2%), driven mainly by da-CS patients. However, the authors found no association between ECMO and reduced in-hospital or 1-year mortality, consistent with recent meta-analyses.2)3) The finding aligns with the ECLS-SHOCK trial, which demonstrated no 180-day mortality benefit of routine venoarterial ECMO in infarct-related CS.4) Caution is warranted in interpreting this registry’s ECMO data, given the relatively modest case numbers and that ECMO was preferentially used in more critically ill patients. While the DanGer Shock trial suggests that device selection may matter, showing survival benefit of a microaxial flow pump in ST-segment elevation myocardial infarction-CS, focus should shift toward optimal MCS selection and precise patient phenotyping rather than a ‘one-size-fits-all’ approach.5) An additional consideration highlighted by this and prior Korean registry analyses is patient heterogeneity. Kim et al.6) reported significant sex differences in clinical characteristics, management patterns, and outcomes among CS patients receiving venoarterial ECMO. Similarly, Park et al.7) also reported sex-specific differences in management and outcomes across ischemic and non-ischemic CS etiologies. These findings suggest that a uniform treatment strategy may not adequately address subgroup-specific vulnerabilities, and that approaches tailored to sex, age, and etiology of CS warrant prospective investigation. From a systems-level standpoint, the persistently high mortality in da-CS demands structured shock team programs. Lee et al.8) demonstrated that a multidisciplinary team approach was associated with significantly better clinical outcomes in patients undergoing extracorporeal cardiopulmonary resuscitation in the emergency department, a finding that suggests organizational readiness is central to managing rapidly deteriorating patients, even if not directly from a da-CS setting. Proactive shock team activation with standardized hemodynamic assessment using the Society for Cardiovascular Angiography and Interventions (SCAI) shock staging framework,9) could enable earlier recognition of impending shock and more timely intervention. Moreover, current evidence suggests that severity alone does not capture the full picture, and recent literature emphasizes moving beyond toward a multi-dimensional approach that includes phenotypes, congestion patterns, and biomarkers.10) Several limitations should be noted. First, the lack of hemodynamic parameters, lactate measurements, and SCAI staging precluded a granular phenotypic characterization. This may have led to the inclusion of patients in SCAI stage B (pre-shock), potentially accounting for the lower mortality rates compared to prior CS cohorts which have reported mortality rates between 38% and 50%.11) Second, the observational nature of this study limits a definitive causal inference. Third, since this study focused exclusively on CS complicating AMI, the findings may not be directly extrapolated to CS of other etiologies, such as acute-on-chronic heart failure or fulminant myocarditis. In summary, Song et al.1) provide a timely and valuable assessment of progress and persistent gaps in the management of CS complicating AMI in Korea over the past decade. While the decreasing incidence of CS and improved outcomes in ba-CS reflect progress, the stagnating mortality in da-CS demands a shift from reactive to proactive management: early identification of at-risk patients, optimized revascularization to prevent shock development, careful selection of MCS and patient-specific MCS deployment, and structured multidisciplinary shock team programs. Only through such a comprehensive, patient-centered approach can we hope to shift the still-unfavorable prognosis of this devastating condition.